The primary objective of NRG Oncology Radiation Therapy Oncology Group 0123 was to test the ability of the angiotensin-converting enzyme inhibitor captopril to alter the incidence of pulmonary damage after radiation therapy for lung cancer; secondary objectives included analyzing pulmonary cytokine expression, quality of life, and the long-term effects of captopril.
T he majority of patients with lung cancer present with locally advanced, unresectable disease; this is managed with primary thoracic irradiation often delivered with or without neoadjuvant or concurrent chemotherapy with continued overall poor survival rates. 1 Radiation pneumonitis and radiation-induced pulmonary fibrosis are refractive to management. As a result, lung tolerance is a major doselimiting factor in the radiotherapeutic management of thoracic tumors. 2 During the 1990s, there was work suggesting that captopril might mitigate radiation-induced pulmonary injury. Ward and colleagues 3, 4 had shown that captopril administration after hemithorax irradiation decreased pulmonary arterial pressure in rats, reduced radiation-induced endothelial dysfunction, reduced pulmonary fibrosis, and delayed the onset of radiation-induced pulmonary arterial hypoperfusion. In addition, rats given chemotherapy and total body irradiation were noted to have significantly less lung parenchymal damage with the addition of captopril, 5 and rats given total body irradiation alone had a decreased incidence of radiation nephropathy when treated with captopril. 6 In most of these studies, captopril was administered after the completion of radiation, in what we would now term mitigation regimens. 7 Captopril was typically effective at dose regimens 12 to 25 times higher than the standard antihypertensive dose in humans, based on equivalent body weight, although on an equivalent body surface area basis the dose is well within the range used in humans. 8 This work suggested a novel application for captopril in the management of radiation injury. Subsequent work has noted that the mitigation effect was a property of many different angiotensin-converting enzyme inhibitors (ACEIs). [9] [10] [11] In addition, some recent clinical studies provide even stronger support for the concept behind the study, as both prospective 9 and retrospective [10] [11] [12] studies have shown evidence that ACEIs can decrease radiation-induced pulmonary injury.
NRG Oncology Radiation Therapy Oncology Group (RTOG) 0123 was also designed to investigate the pulmonary expression of CCL3, tumor necrosis factor-a, interleukin (IL)-1 and IL-6 at specific time intervals after irradiation. RTOG 91-03 found that elevated serum IL-6 after 10 Gy of lung irradiation was associated with grade 2 + acute lung toxicity. 13 The role of these cytokines required further study.
MATERIALS AND METHODS

Study Objectives
NRG Oncology RTOG 0123 had 4 study objectives: (1) Test the ability of captopril to alter the incidence of pulmonary damage at 12 months after completion of radiotherapy (primary endpoint); (2) Investigate the pulmonary expression of CCL3, TNFa, IL-1, and IL-6 at specific time intervals; (3) Prospectively analyze whether the European Organization for Research and Treatment for Cancer (EORTC) Quality-of-Life Questionnaire (QLQ-C30), and the lung cancer module (QLQ-L13) scales are consistent in their measurement of pretherapy symptoms and ensuing changes after therapy for patients with primary lung cancer, including effects related to the addition of captopril; (4) Determine if captopril's effect on pulmonary toxicity persists after completion of drug delivery.
Eligibility Criteria
Study patients had stage II-IIIB non-small cell lung cancer, stage I central non-small cell lung cancer, or limitedstage small cell lung cancer (nonmetastatic disease that would be receiving radiotherapy confined to a single treatment area and chemotherapy). Patients were Z18 years of age and had a Zubrod Performance Status of 0 to 1. The planned total dose of radiotherapy, Z45 Gy, was delivered to the target volume, with >25% of total lung volume receiving >20 Gy if receiving radiotherapy alone. Patients with <25% of the lung receiving >20 Gy were only eligible if receiving concurrent chemoradiotherapy. Lobectomy or segmentectomy was allowed, as was induction or concomitant chemotherapy (either during radiotherapy or during therapy with captopril).
Patients had to meet the following pretreatment evaluation criteria: systolic blood pressure (BP) >110, diastolic BP >60, absolute granulocyte count Z1000/mm Trial Design NRG Oncology RTOG 0123 was a multi-institution randomized phase II trial in which the observational control arm was incorporated to determine pulmonary toxicity rates in the current patient population. Patients registered to the trial during radiation therapy (RT). Patients meeting pretreatment evaluation criteria at the completion of RT were eligible to continue to the randomization portion of the trial. Specifically, patients with a resting BP < 110/60 were not permitted to continue. Patients were stratified according to amount of lung irradiated to >20 Gy (25 to 37%, >37%), prior lung surgery (no vs. yes), and chemotherapy (no vs. yes). Patients were then randomized to the captopril treatment or observation arm within 48 hours before completion of RT, and captopril therapy was to begin the first business day after completing radiotherapy. Patients randomized to captopril were administered a 6.25 mg test dose pill before beginning treatment. Patients were scheduled to receive 12.5 mg three times a day (tid), 1 hour before meals for weeks 1 to 2, 25 mg tid for weeks 3 to 4, and 50 mg tid for weeks 5 to 52. Patients with a resting BP < 110/60 did not escalate to the next dose level and remained on the current dose level. Randomization was performed using the Zelen 14 treatment allocation scheme to balance patient factors and institution. Patients were evaluated weekly for adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) 
Statistical Methods
The primary endpoint of the study was incidence of grade 2 + radiation-induced pulmonary toxicity within 1 year after completion of radiation. Assuming that the incidence of pulmonary toxicity would be 50%, based on Fisher exact test with a significance level of 0.05 (1-sided), 168 randomized patients would be required to have 80% statistical power to detect a 40% relative reduction (from 50% to 30%) in the number of patients experiencing pulmonary toxicity while receiving captopril. Assuming that 15% of cases would not continue to the randomization stage and 5% of patients would be found retrospectively ineligible, the target sample size was set at 205 patients. Patients that received no captopril or just the test dose, or were lost to follow-up or died within the first year before experiencing a radiation-induced pulmonary toxicity, were excluded from analysis of the primary endpoint.
RESULTS
NRG Oncology RTOG 0123 accrued 81 patients between June 2003 and August 2007 for an average monthly accrual of 1.6 patients. The trial closed early due to slow accrual. Patients were followed for a minimum of 12 months. Three patients did not meet the eligibility criteria at registration. Of the 78 eligible patients, 17 (22%) were randomized to the observation arm, 16 (21%) were randomized to receive captopril, and 45 (58%) did not reach the randomization phase. Of these 45 patients 5 withdrew consent. Forty patients were not randomized postradiation due to patients' refusal, 11 physician preference, 6 ineligibility for randomization, 5 adverse event during RT, 3 disease progression/death, 4 or not specified. 11 There were 4 patient deaths due to lung cancer in the observation arm; there was 1 patient death due to lung cancer and 2 patients lost to follow-up in the captopril arm. Six patients randomized to receive captopril did not begin study drug treatment due to either an adverse drug reaction to the test dose (in their case, hypotension) or patient refusal to begin the study drug, and thus were excluded. Thus, of the 33 randomized patients, 20 were analyzable (13 observation, 7 captopril) (Fig. 2) . Patient characteristics were well balanced between the observation and captopril treatment arms (Table 1) .
Treatment compliance was reported for the first 5 weeks of study drug treatment during the dose escalation phase. Treatment compliance beyond 5 weeks was monitored by institution and not reported centrally. Of the 10 patients that started captopril treatment, 6 (60%) completed treatment per protocol and escalated to the 50 mg regimen and 4 (40%) discontinued treatment due to side effects. Of the 4 cases discontinuing treatment before 5 weeks, 2 cases completed 2 weeks of treatment with a maximum dose of 12.5 mg, 1 case completed 4 weeks of treatment with a maximum dose of 12.5 mg, and 1 case completed 4 weeks of treatment with a maximum dose of 50 mg.
Since the number of patients reaching the randomization phase (33) was much less than anticipated (168), the study did not have sufficient power to detect the projected 40% reduction in pulmonary toxicity due to captopril. Given the actual sample size, the power would have been 25%. P-values are not reported as the following is a descriptive analysis of the study results.
The median follow-up time for the 20 analyzable patients included was 16.5 months (range, 3.4 to 30.0 mo). The incidence of grade 2 + pulmonary toxicity attributed to radiation was 14% (1/7) and 23% (3/13) in the captopril and observation treatment arms, respectively. The incidence of all grade 2 + pulmonary toxicities was 57% (4/7) and 39% (5/13) in the captopril and observation treatment arms, respectively (Table 2) . Table 3 lists all 9 grade 2 + pulmonary toxicities along with treatment and modality attributions. Owing to the small number of patients accrued and low compliance on the EORTC QLQ-C30 and EORTC QLQ-LC13 assessments, quality of life and the cytokines were not analyzed.
DISCUSSION
The clinical syndromes of pneumonitis and fibrosis are associated with RT and several cytotoxic drugs, including bleomycin and methotrexate. The disease course is biphasic and is dependent upon the dose and volume of lung exposed. Lower doses of lung irradiation produce subclinical pathologic effects that can be expressed by added insult such as infection or drugs. Clinical manifestations typically occur 1 to 3 months after completion of RT or drug therapy; occasionally, an accelerated phase of the syndrome results within days after an offending drug is administered. There may be a low-grade fever along with respiratory symptoms such as congestion and cough. In more severe cases, dyspnea and pleuritic chest pain may be present. When tolerance doses are exceeded, pneumonitis can be very severe and produce acute respiratory distress along with spiking fever, acute cor pulmonale, or death. 15 Patients who survive this period experience a protracted period of pneumonitis that can last from days to months.
After the acute symptoms, there is an intermediate phase during which histologic changes continue, but in which the symptoms are not as marked. This eventually progresses to a fibrotic phase. Chronic effects of cytotoxic therapy are observed from months to years after treatment. Pulmonary fibrosis develops insidiously in the previously irradiated field, but stabilizes after 1 to 2 years. Most patients with radiation pulmonary fibrosis are asymptomatic. In a few patients, chronic respiratory failure may be present with symptoms such as dyspnea on exertion, cyanosis, or chronic cor pulmonale. Corresponding changes in pulmonary function tests are measured as a reduction in tidal volume and minute ventilation, and an increase in respiratory rate. Improvement in pulmonary function resulting from radiation response of lung tumor may compensate for losses caused by radiation fibrosis. 16 The incidence of radiation pneumonitis has been correlated with the percentage of total lung receiving >20 Gy. In 1 series, when the percentage of total lung volume receiving >20 Gy was <25%, the incidence of pneumonitis was 0% to 4%. When the total lung volume receiving >20 Gy was 25% to 37%, the incidence of pneumonitis was 2% to 12%. When the total lung volume receiving >20 Gy was >37%, the incidence of pneumonitis rose to 19% to 30%. 17 Several randomized trials have shown survival advantages in patients receiving higher dosages of RT. In the RTOG 73-01 study, 376 patients were randomized between a radiation dose of 40 Gy split course and a continuous fractionation schedule of 40, 50, or 60 Gy; all patients were treated with 2-dimensional treatment techniques. The local-regional failure rates at 3 years in the different arms were 44%, 52%, 42%, and 33%, respectively. 18 Strategies to increase pulmonary tolerance to radiation might enable the oncologist to treat localregional lung cancer more aggressively. NRG Oncology RTOG 0123 sought to investigate the utility of the ACEI captopril in this regard.
Interest in the concept of mitigating radiation-induced pulmonary injury with ACEIs remains strong despite the failure of this study to accrue an adequate number of patients. The basic concept now has the active support of the National Cancer Institute, 19 and there is a growing base of experimental 9-11 and clinical [9] [10] [11] [12] evidence that supports the efficacy of this approach.
This trial failed for 2 reasons, low accrual and a surprising large number of accrued patients who were not analyzable ( > 75% loss rather than the anticipated 20%). It has been suggested that a major problem was "the difficulty lung cancer patients have taking a blood pressure medication"; however, since a large number of lung cancer patients ( > 40% in a recent retrospective study 14 ) are already taking such drugs, this is unlikely to be the critical issue. Informal discussions with some of the investigators and data managers suggest that there were at least 2 other factors: the extra patient visits required for the 5-week drug escalation period, and a tid drug schedule. There are potential solutions to both issues. First, the newer generation of ACEIs are taken only once per day, and some of these (eg, enalapril) have mitigation efficacy in experimental models at least as good as that found for captopril. 5, 9, 11 Second, as there is now strong experimental 20 and clinical [10] [11] [12] evidence that the use of ACEIs during cancer therapy is safe, ACEI dose escalation could be done before the end of radiotherapy. In fact, a pilot study at Mayo Clinic in preparation for a larger Alliance for Clinical Trials in Oncology study is looking at the safety of lisinopril versus placebo starting within 7 days of thoracic RT to try to mitigate radiation pneumonitis (ClinicalTrials.gov Identifier: NCT01880528). As expected, the biggest problem with these types of trials is the large number of lung cancer patients who are already on ACEIs and other antihypertensives [10] [11] [12] and who would hence be ineligible for the trial.
CONCLUSIONS
In summary, although NRG Oncology RTOG 0123 did not accrue enough patients to assess efficacy, it did show the safety of such an approach and suggests that the use of newer ACEIs (eg, enalapril or lisinopril) started during radiotherapy should solve many of the accrual problems faced by this trial. 
